8-K: Niagen Bioscience Secures Full NR Patent Portfolio

Niagen Bioscience has acquired the entire Nicotinamide Riboside (NR) patent portfolio from Queens University Belfast, consolidating its intellectual property leadership in the NAD+ industry.

Summary

• Niagen Bioscience, through its wholly owned subsidiary ChromaDex, Inc., executed an assignment agreement with Queens University Belfast (QUB) on December 18, 2025, effective December 16, 2025.
• This agreement replaces and terminates the previous Joint Ownership and Management Agreement (JOMA) dated October 9, 2015, and the License Agreement dated November 23, 2015.
• QUB assigned all its right, title, and interest in the patent rights previously jointly owned or licensed to ChromaDex, granting Niagen Bioscience sole ownership of the Nicotinamide Riboside (NR) patent portfolio.
• QUB provided a broad release of all royalty, payment, accounting, and other obligations arising under the prior agreements, including those accrued by ChromaDex through 2025.
• As consideration, Niagen Bioscience agreed to make a one-time payment of approximately $1,004,697 in 2025, in lieu of accrued royalties through 2024.
• Future payments to QUB include annual payments of $500,000 (USD) and 35,000 (GBP) between 2026 and 2038.
• Additional one-time payments of $1,500,000 (USD) in 2034 and $2,000,000 (USD) in 2037 are also part of the agreement.

Sentiment

Score: 8

Explanation: The acquisition of the full NR patent portfolio is a highly strategic move that significantly strengthens Niagen Bioscience's competitive position and intellectual property defenses. While there are substantial future payment obligations, the long-term benefits of sole ownership and increased operational flexibility outweigh the costs, especially given the release from past royalties. This move solidifies the company's leadership in the NAD+ space.

Positives

• Niagen Bioscience now holds sole ownership of the core Nicotinamide Riboside (NR) patent portfolio, significantly strengthening its intellectual property position and market leadership in the NAD+ industry.
• The acquisition provides enhanced financial, strategic, and operational flexibility, including greater control over the molecules for current and future applications, particularly for pharmaceutical uses.
• It increases optionality in how the intellectual property is developed, partnered, or licensed, allowing for more strategic business decisions.
• The company is released from all past royalty, payment, and accounting obligations under the previous agreements through 2025, providing financial relief and clarity.
• Composition-of-matter patents, widely regarded as the strongest form of IP protection, are now fully owned, which further protects Niagen Bioscience shareholders against infringers of all known forms of NR.
• The company's intellectual property estate now includes more than 90 issued and pending patents worldwide across NR and other NAD+ precursors, with over 50 focused solely on NR.

Negatives

• Niagen Bioscience has committed to significant future payment obligations to Queens University Belfast, including a one-time payment of approximately $1,004,697 in 2025, annual payments of $500,000 (USD) and 35,000 (GBP) from 2026 to 2038, and additional one-time payments of $1,500,000 (USD) in 2034 and $2,000,000 (USD) in 2037.

Risks

• Inflationary conditions and adverse economic conditions could impact financial performance.
• The company has a history of operating losses.
• Ability to maintain and grow product sales, marketing, and distribution capabilities is crucial for future success.
• Changing consumer perceptions of products could affect demand.
• Reliance on a single or limited number of third-party suppliers poses supply chain risks.
• Risks associated with conducting business in China, including unanticipated developments.
• Challenges related to securing adequate quantities of pharmaceutical-grade Niagen in a timely manner.
• Ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities for pharmaceutical-grade Niagen distribution.
• Maintaining the company's position on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list.
• Ability to maintain and enforce existing intellectual property and obtain new patents is critical.
• Uncertainty regarding whether the potential benefits of NRC can be further supported by research.
• Further research and development and the results of clinical trials may be unsuccessful or insufficient to meet regulatory standards or warrant continued development.
• Challenges in enrolling sufficient numbers of subjects in clinical trials.
• Determinations made by the FDA and other governmental authorities, including with respect to competing products.
• Economic and market instability, including as a result of tariffs or trade conflicts.

Future Outlook

The company expects to gain enhanced financial, strategic, and operational flexibility, including greater control over its molecules for current and future applications, particularly for pharmaceutical uses. This acquisition also provides increased optionality in how the intellectual property is developed, partnered, or licensed. The company continues to evaluate next-generation NAD+ precursors while maintaining a robust IP position.

Management Comments

• "This transaction consolidates the most important intellectual property underlying our NR business into Niagen Bioscience outright."
• "Composition of matter patents are the strongest form of IP protection, and owning this portfolio further protects Niagen Bioscience shareholders against infringers of all known forms of the greatest precursor to NAD, NR."

Industry Context

This acquisition solidifies Niagen Bioscience's leadership in the NAD+ industry by making it the sole owner of a comprehensive and defensible intellectual property portfolio related to Nicotinamide Riboside (NR). This move enhances its competitive advantage against other companies in the healthy aging and supplement markets, particularly those developing NAD+ precursors. The emphasis on "composition of matter patents" suggests a strategic move to secure foundational IP, which is critical in the rapidly evolving biotechnology and supplement space.

Stakeholder Impact

• Shareholders: Expected to benefit from strengthened intellectual property, reduced risk from infringers, enhanced strategic flexibility, and potential for increased long-term value.
• Employees: Potential for increased stability and growth opportunities due to a stronger market position and expanded control over core assets.
• Customers: Continued access to Niagen products with potentially enhanced innovation and supply chain control.
• Queens University Belfast: Will receive significant payments over time, providing a clear financial benefit for their past research and IP contributions.

Next Steps

• Make scheduled payments to Queens University Belfast through 2038.
• Continue to develop, partner, or license the acquired intellectual property.
• Continue evaluating next-generation NAD+ precursors.
• Maintain and enforce existing intellectual property and obtain new patents.
• Secure adequate quantities of pharmaceutical-grade Niagen and obtain appropriate contracts with FDA-registered 503B outsourcing facilities.
• Ensure the company remains on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B Category 1 list.

Key Dates

Recommendation

The acquisition of the entire Nicotinamide Riboside (NR) patent portfolio from Queens University Belfast is a highly strategic and value-accretive move for Niagen Bioscience. Gaining sole ownership of foundational composition-of-matter patents provides the strongest possible intellectual property protection, significantly reducing competitive threats and infringement risks in the rapidly growing NAD+ market. This consolidation enhances the company's long-term competitive moat, offers greater control over product development and commercialization, and provides substantial operational and strategic flexibility. The release from past royalty obligations further sweetens the deal, despite the future payment schedule. This move solidifies Niagen Bioscience's position as the undisputed leader in NAD+ science and innovation, making it a compelling "strong buy" for investors seeking exposure to the healthy aging and biotechnology sectors.

Keywords

Niagen Bioscience, ChromaDex, Queens University Belfast, NAD+, Nicotinamide Riboside, NR, Patent Acquisition, Intellectual Property, IP Portfolio, Healthy Aging, Pharmaceutical Applications, Tru Niagen, Niagen Plus, Biotechnology, Life Sciences